Andrew Er is a Chartered Accountant with 20 years of working experience with a large proportion being in healthcare and financial businesses. He has led both investment in and management of healthcare businesses. He has completed the Healthcare Administrators program from Parkway in 1999.
In the accounting and finance world he has previously worked for ANZ Banking Group, Ernst & Young and Mazars. He was a founding partner and director of boutique corporate finance house, Stirling Coleman Limited which specialised in taking companies for IPO.
In the healthcare arena, Andrew was a lead in business development at the Parkway Group. He was responsible for setting up the Casemix system (hospital classification and costing system) which was implemented throughout the Group. On the business development side he helped set up the Gleneagles Clinical Research Centre and the Day Surgery Centre. He has also served as the General Manager at Asiamedic Limited, as a Director at Gleneagles Dialysis Centre and Health Kind International Ltd.
Andrew currently also serves as a VP for Investments in Oriens Asset Management, a private equity firm specialised in Healthcare and Infrastructure investment. He is a Director of FCC Partners, an Asian focused boutique investment bank involved in cross boarder transactions.
He is currently also the Chairman for the Chartered Accountants Australia and New Zealand (CA ANZ), Singapore Members Committee.
Dr. Goh Jin Hian
Dr. Goh obtained his Bachelor of Medicine and Bachelor of Surgery from the National University of Singapore in 1992. He also holds a Master of Business Administration from the University of Hull. In addition, Dr. Goh completed the Wharton Advanced Management Program in 2005.
He has he held several senior executive positions in Parkway Holdings Ltd (now IHH Ltd) from 1999 to 2011, including Chief Executive Officer of Gleneagles Hospital, President of Singapore Operations and Senior Vice-President of Growth, Innovation & Strategy. He served as Executive Consultant of ParkwayHealth, Singapore from April 2011 to March 2015. Currently, he remains a Director on two of Parkway’s subsidiaries, namely, Parkway Shenton Pte Ltd and Shenton Insurance Pte Ltd.
Dr. Goh assumed the position of Chief Executive Officer and Director of New Silkroutes Group Limited, a company listed on the Singapore Exchange, on July, 2015. The company is an investment holding company with interests in the energy and technology sectors.
Dr. Dominic Er
Holds a Bachelor of Medicine and Bachelor of Surgery degree from the University of Queensland, Australia. He is a fellow of the Royal College of Physicians London and the Academy of Medicine, Singapore.
A qualified ‘Internal Medicine’ practitioner and Nephrologist, Dr. Er performed the first spousal kidney transplant in Gleneagles Hospital Singapore. He subsequently ventured into healthcare administration. He set up numerous private dialysis centres in Singapore and in the region which included partnerships with Parkway Group and multinational suppliers such as Fresenius, Baxter and B Braun.
He was a founding shareholder and doctor at Johor Specialist Medical Centre in Johor Bahru. He has served as Group General Manager of the Parkway Group (now know as IHH) and CEO of Gleneagles Hospital. He was a founder of the Gleneagles Clinical Research Centre.
Dr. Er has previously served as the Managing Director of Asiamedic Ltd and is former owner and Co-Chairman of Wuxi New District Phoenix Hospital.
Dr. Akira Wu
MBBS (Qld), FRCP (Lond), FAMS
Consultant Nephrologist and Physician at the Mount Elizabeth Medical Centre. He was previously a Nephrologist (Department of Renal Medicine) at the Singapore General Hospital and a Nephrologist at Prince Henry’s Hospital in Melbourne, Australia.
He received his MBBS from Monash University, Melbourne, Australia (1974). In 1981, he was awarded the Prince Henry’s Hospital Full-Time Specialist Scholarship to be a Renal Research Fellow. He is a Fellow of the Royal Australasian College of Physicians (1981) and the Academy of Medicine, Singapore (1991).
Dr Wu has authored or co-authored widely in peer-reviewed international journals. He is a member of the National Committee on Renal Care, the Singapore Renal Registry and the Drug Evaluation Centre, Health Sciences Authority. He was previously the Chairman, Medical Advisory Board and Continuous Medical Education Committee of Mount Elizabeth Hospital. His membership of societies includes: the International Society of Nephrology, the American Society of Nephrology, the Australasian Society of Nephrology, the American Society of Hypertension and the European Renal Association & European Dialysis & Transplant Association. He is currently the Treasurer of Singapore Hypertension Society.
Dr. Jeremy Chapman
Dr Jeremy Chapman is a renal physician with a special interest in transplantation. He is Clinical Director Division of Medicine and Cancer, Westmead Hospital and Director of Western Renal Services, Chair of the Westmead Research Committee, Consultant to the NSW Australian Red Cross Blood Service Tissue Typing Laboratory and Chairman of the Australian Bone Marrow Donor Registry, the Australian Cord Blood Bank Network and Past President of the Transplantation Society of Australia and New Zealand. He is a member of the Advisory Council of the Australian Organ and Tissue Authority and Western Sydney Local Health District Board.
He is a Past-President of The Transplantation Society, Advisory Member of The World Health Organisation Expert Advisory Panel on Human Cell Tissue and Organ Transplantation, Secretary General and Past President of the World Marrow Donor Association and founding CoChair of the Declaration of Istanbul Custodian Group. He received the Asturias Foundation 2010 Award for International Cooperation on behalf of The Transplantation Society. He was awarded the 2010 David Hume Award of the US National Kidney Foundation. He was awarded Companion of the Order of Australia in 2015. He is the Editor-in-Chief for Transplantation and Transplantation Direct 2015-2020.
Professor Chapman’s clinical work is in renal medicine, transplantation of kidney and pancreas and diabetic renal disease and islet transplantation.
Professor Chapman is actively involved in the academic field having over 360 publications. He is a Clinical Professor at the University of Sydney, a Fellow of the Royal College of Physicians in the United Kingdom and Fellow of the Royal Australasian College of Physicians.
Mr. Peter Eu
B.Sc (Pharmacy), M.Sc (Radiopharmacy)
Peter Eu is a Pharmacist with over 30 year of experience. He is currently serving as a Radiopharmacist with the Peter MacCallum Cancer Hospital. He is also an Associate Professor Co-joint at School of Medicine, Deakin University.
He set up one of the first privately operated centralised Radiopharmacy in Australia which served almost all the nuclear medicine practices in the states of Victoria and South Australia. He operated the first dedicated clinical PET cyclotron to produce PET radiopharmaceuticals.
In the academic domain, he presented the first post-graduate distance education Radiopharmacy course in Australia for Pharmacists to be jointly offered by the Society of Hospital Pharmacists, Australia and College of Pharmacy, Monash University. He co-wrote and then acted as course advisor for the Radiopharmacy Accreditation Program, Monash University. He was also a former Co-Director of the first private cyclotron unit and the first private Positron Emission Tomography (PET) centralised Radiopharmacy in Australia.
Peter is also familiar with South East Asia. He was an External Consultant to the first Cyclotron and PET Centralised Radiopharmacy in Singapore. He was Consultant Radiopharmacist to the PET/CT Centre, AsiaMedic Specialist Centre, Singapore.
He is a Co-founder and Director of a specialised compounding (radio)pharmacy supplying niche products including sponsored clinical trials in Australia.
Corporate Profile & Business
Quantum Health Private Limited (“QH” or the “Company”) and our subsidiaries are involved in healthcare related businesses. We are based in Singapore and our geographic focus is on the ASEAN, Australia and China. Our 3 key business segments are direct healthcare investment, healthcare & business consultancy and investment into healthcare private equity funds. The Company was incorporated on 30 August 2003 in Singapore, as a private exempt company limited by shares under the Companies Act, Republic of Singapore.